Australia markets closed

Roche Holding AG (0QOK.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
324.74-7.01 (-2.11%)
At close: 05:20PM GMT
Full screen
Previous close331.75
BidN/A x N/A
AskN/A x N/A
Day's range322.70 - 328.15
52-week range322.70 - 328.15
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.18
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Roche Alzheimer’s disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis

    The Elecsys® Alzheimer’s disease (AD) CSF assays will be available on the cobas fully automated immunoassay analyzers, enabling patients to get broad access to high quality testing in a timely manner.Greater accessibility and lower cost means these assays could accelerate the path to diagnosis for people with Alzheimer’s disease.The assays are easily scalable to meet the imminent demand for Alzheimer’s disease modifying therapies as they become available. Basel, 8 December 2022 - Roche (SIX: RO,

  • PR Newswire

    Roche Announces Brad Moore as President and CEO of Roche Diagnostics North America

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Brad Moore as president and CEO of Roche Diagnostics North America, effective January 1, 2023. Moore currently serves as senior vice president, Core Lab and Point of Care, within Roche Diagnostics North America.

  • GlobeNewswire

    Roche receives U.S. FDA Emergency Use Authorization for its high-throughput test to detect monkeypox virus

    In May 2022, Roche was one of the first companies to develop a suite of tests to detect the monkeypox virus and aid in the understanding of why and how the disease is spreading. cobas MPXV for use on cobas 6800/8800 Systems is the first monkeypox virus test granted EUA following evaluation in actual patient samples rather than just samples formulated in the laboratory. High-throughput solutions enable rapid results, allowing individuals to avoid additional testing or unnecessary isolation, and s